Prognostic Impact of NQO1 in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC)  Treated with Concomitant Chemoradiotherapy

Celalettin Eroğlu; Olgun Kontaş; Ahmet Öztürk

Makale detayları

Prognostic Impact of NQO1 in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC) Treated with Concomitant Chemoradiotherapy

Yazarlar:

Celalettin Eroğlu | Olgun Kontaş | Ahmet Öztürk

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 1, pp.67-72

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001285374

pISSN:

1303-6610

Anahtar kelimeler:

Özet:

 Objective: In this study, we aimed to determine the predictive and prognostic value of NQO1 in patients with stage III non-small cell lung cancers NSCLC treated with concomitant chemoradiotherapy. Materials and Methods: 64 patients with stage III NSCLC treated with concomitant cisplatin  docetaxel chemoradiotherapy were enrolled to the study. NQO1 immunohistochemical IHC staining was performed on the pathology preparations of the patients and compared in terms of the negative and positivity. Results: The median age was 63 range, 35-83 years. Most of the patients 86, n55 were male. 27 n17 of the patients were stage IIIA, 56 n36 were stage IIIB, and 17 n11 were stage IIIC. The patients were histopathologically classified as 47 n30 adenocarcinoma, 47 n30 as epidermoid carcinoma, and 6 n4 as NSCLC, Not otherwise specified. Median follow-up was 20 months range, 3-7 months. As a result of the IHC staining of NQO1, 7 11 of the 64 patients were negative, 11 17 of the 64 patients were  positive, 14 22 of the 64 patients were  positive and 32 50 of the 64 patients were  positive. Median overall survival of patients according to NQO1; was found 21 months in -s, 19 months in s, 16 months in s and 19 months in s. Although the median overall survival in patients with positive NQO1 was numerically lower than in patients with negative NQO1, which was not statistically significant p0.801. Conclusion: NQO1 may be a prognostic factor in patients with stage III NSCLC treated with concomitant chemoradiotherapy, but further studies with a larger number of patients are needed.

 Objective: In this study, we aimed to determine the predictive and prognostic value of NQO1 in patients with stage III non-small cell lung cancers NSCLC treated with concomitant chemoradiotherapy. Materials and Methods: 64 patients with stage III NSCLC treated with concomitant cisplatin  docetaxel chemoradiotherapy were enrolled to the study. NQO1 immunohistochemical IHC staining was performed on the pathology preparations of the patients and compared in terms of the negative and positivity. Results: The median age was 63 range, 35-83 years. Most of the patients 86, n55 were male. 27 n17 of the patients were stage IIIA, 56 n36 were stage IIIB, and 17 n11 were stage IIIC. The patients were histopathologically classified as 47 n30 adenocarcinoma, 47 n30 as epidermoid carcinoma, and 6 n4 as NSCLC, Not otherwise specified. Median follow-up was 20 months range, 3-7 months. As a result of the IHC staining of NQO1, 7 11 of the 64 patients were negative, 11 17 of the 64 patients were  positive, 14 22 of the 64 patients were  positive and 32 50 of the 64 patients were  positive. Median overall survival of patients according to NQO1; was found 21 months in -s, 19 months in s, 16 months in s and 19 months in s. Although the median overall survival in patients with positive NQO1 was numerically lower than in patients with negative NQO1, which was not statistically significant p0.801. Conclusion: NQO1 may be a prognostic factor in patients with stage III NSCLC treated with concomitant chemoradiotherapy, but further studies with a larger number of patients are needed.

 Objective: In this study, we aimed to determine the predictive and prognostic value of NQO1 in patients with stage III non-small cell lung cancers NSCLC treated with concomitant chemoradiotherapy. Materials and Methods: 64 patients with stage III NSCLC treated with concomitant cisplatin  docetaxel chemoradiotherapy were enrolled to the study. NQO1 immunohistochemical IHC staining was performed on the pathology preparations of the patients and compared in terms of the negative and positivity. Results: The median age was 63 range, 35-83 years. Most of the patients 86, n55 were male. 27 n17 of the patients were stage IIIA, 56 n36 were stage IIIB, and 17 n11 were stage IIIC. The patients were histopathologically classified as 47 n30 adenocarcinoma, 47 n30 as epidermoid carcinoma, and 6 n4 as NSCLC, Not otherwise specified. Median follow-up was 20 months range, 3-7 months. As a result of the IHC staining of NQO1, 7 11 of the 64 patients were negative, 11 17 of the 64 patients were  positive, 14 22 of the 64 patients were  positive and 32 50 of the 64 patients were  positive. Median overall survival of patients according to NQO1; was found 21 months in -s, 19 months in s, 16 months in s and 19 months in s. Although the median overall survival in patients with positive NQO1 was numerically lower than in patients with negative NQO1, which was not statistically significant p0.801. Conclusion: NQO1 may be a prognostic factor in patients with stage III NSCLC treated with concomitant chemoradiotherapy, but further studies with a larger number of patients are needed.

 Amaç: Bu çalışmada da eşzamanlı kemoradyoterapi ile tedavi edilen evre III küçük hücreli dışı akciğer kanseri KHDAKli hastalarda NQO1in prediktif ve prognostik öneminin tespiti amaçlandı. Gereç ve Yöntemler: Bu çalışmaya eşzamanlı cisplatindosetaksel kemoradyoterapisi ile tedavi edilen evre III 64 KHDAKli olgu dahil edildi. Hastaların patoloji preparatlarında NQO1 immünohistokimyasal İHK boyama yapılarak negatif ve pozitiflik açısından karşılaştırıldı. Bulgular: Medyan yaş 63 sınırlar, 35-83 olup olguların 86 n55sı erkek idi. Olguların 27 n17si evre IIIA, 56 n36sı evre IIIB ve 17 n11si evre IIIC idi. Olgular histopatolojik olarak 47 n30 adenokarsinom, 47 n47si epidermoid karsinom ve 6 n4sı alt tipi belirlenemeyen KHDAK şeklinde sınıflandı. Medyan takip süresi 20 ay sınırlar, 3-7 ay bulundu. NQO1in İHK boyaması sonucunda olguların 7 11si negatif, 11 17i  pozitif, 14 22ü  pozitif ve 32 50si  pozitif olarak bulundu. Olguların NQO1e göre medyan genel sağkalımı; -lerde 21 ay, lerde 19 ay, lerde 16 ay ve lerde 19 ay bulundu. Pozitif NQO1 olan olgularda medyan genel sağkalım sayısal olarak negatif olan olgulardan daha düşük olmasına rağmen istatistiksel olarak anlamlı bulunmadı p0.801. Sonuç: Eşzamanlı kemoradyoterapi ile tedavi edilen evre III KHDAKli hastalarda NQO1 prognostik faktör olabilir ancak çok hasta sayılı çalışmalara ihtiyaç vardır.

Makale detayları

Prognostic Impact of NQO1 in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC) Treated with Concomitant Chemoradiotherapy

Yazarlar:

Celalettin Eroğlu | Olgun Kontaş | Ahmet Öztürk

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 1, pp.67-72

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001285374

pISSN:

1303-6610

NON SMALL CELL CANCER

CONCOMİTANT CHEMORADİOTHERAPY

NQO1

KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİ

EŞZAMANLI KEMORADYOTERAPİ

NQO1

Sayı

Makale detayları

Prognostic Impact of NQO1 in Patients with Stage III Non-Small Cell Lung Cancer (NSCLC) Treated with Concomitant Chemoradiotherapy

Yazarlar: Celalettin Eroğlu | Olgun Kontaş | Ahmet Öztürk

Yayıncı: Kahramanmaras Sutcu Imam University

Ana Başlıklar: Sağlık Kurumları Yönetimi

Dergi: Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 1, pp.67-72

Belge Tipi: Makale

Yayın Tarihi: 3/2023

Belge Dili: Türkçe

Document ID (Org No.): 2001285374

pISSN: 1303-6610

NON SMALL CELL CANCER

CONCOMİTANT CHEMORADİOTHERAPY

NQO1

KÜÇÜK HÜCRELİ DIŞI AKCİĞER KANSERİ

EŞZAMANLI KEMORADYOTERAPİ

NQO1

Sayı

Yazarlar:

Celalettin Eroğlu | Olgun Kontaş | Ahmet Öztürk

Yayıncı:

Kahramanmaras Sutcu Imam University

Ana Başlıklar:

Sağlık Kurumları Yönetimi

Dergi:

Kahramanmaraş Sütçü İmam Üniversitesi Tıp Fakültesi Dergisi Vol.18 Issue 1, pp.67-72

Belge Tipi:

Makale

Yayın Tarihi:

3/2023

Belge Dili:

Türkçe

Document ID (Org No.):

2001285374

pISSN:

1303-6610